Yisheng Biopharma Co., Ltd. (“Yisheng Biopharma”), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of immunological biologics and vaccines, announced today that an abstract has been accepted for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2019, which will be held from March 29 through April 3, 2019 at the Georgia World Congress Center in Atlanta, GA.
Yisheng Biopharma will give a poster presentation highlighting preclinical data of its clinical-stage candidate, YS-ON-001, a systemically and locally administered immune-oncology therapy. The U.S. Food and Drug Administration (FDA) granted YS-ON-001 two orphan drug designations (ODD) for the treatment of pancreatic cancer and hepatocellular carcinoma. YS-ON-001has demonstrated its unique immunomodulating mechanisms, effective changes of tumor microenvironment and broad spectrum of anti-tumor activity either as standalone therapy or in combination therapies with radiation, chemo, targeted therapies and PD-1 checkpoint inhibitors.
“We are pleased to be invited to present detailed research results of YS-ON-001 for the first time at an oncology forum. YS-ON-001 was recently accepted for clinical trial application by the National Medical Products Administration (NMPA)of China and we look forward to initiating clinical studies in China this year. This product is currently in clinical development in Singapore and was recently approved for treatment of advanced solid tumors under the brand name of Yivyka(TM) in Cambodia. We are very pleased to see hundreds of cancer patients received the treatment of Yivyka(TM). We are looking forward to sharing more clinical data of this product at appropriate venues in the future,” said Zhongkai Shi, M.D., Chief Medical Officer of Yisheng Biopharma.
About Yisheng Biopharma Co., Ltd.
Yisheng Biopharma is a global, fully integrated biopharmaceutical company engaged in discovering, developing and commercializing innovative biotherapeutics for cancer and infectious disease using its novel PIKA® immunomodulating technology. PIKA technology augments both innate and adaptive immune responses through the TLR3, RIG-I and MDA5 pathways. Products in clinical development include YS-ON-001 for the treatment of advanced solid tumors, YS-HBV-001 hepatitis B vaccine, and the PIKA rabies vaccine for accelerated protection against rabies infection. The Company has two marketed products in China and South Asia market. Yisheng Biopharma is headquartered in Beijingwith approximately 640 employees in China, Singapore, Cambodia and the U.S.